Key terms
About PASG
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PASG news
Apr 01
7:21am ET
Analysts’ Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
Mar 26
7:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
Mar 05
1:01am ET
New Innovation / R&D Risk for Passage Bio, Inc. – What’s the Latest?
Mar 04
4:11pm ET
Passage Bio files $200M mixed securities shelf
Mar 04
7:02am ET
Passage Bio reports Q4 EPS (30c), consensus (40c)
No recent press releases are available for PASG
PASG Financials
Key terms
Ad Feedback
PASG Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PASG Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range